ReportWire

Tag: fuel costs

  • How to save money this Labor Day weekend

    [ad_1]

    (CNN) — As Americans prepare for the last holiday weekend of the summer, many are looking to cut travel costs as much as they can.

    Travelers are already paying less for domestic plane tickets, rental cars and hotel stays – the cost of which are all down compared to last year, according to AAA, the automotive and trip-planning group. But even with those savings, Deloitte’s Summer Travel Survey found that Americans are embracing a “more frugal approach” to traveling this summer.

    For those looking to go on a late summer trip — something travelers are increasingly opting for — here are some ways to save.

    Plan your trip in advance, mapping out gas stops

    Gas prices have come down substantially from their 2022 peak, but drivers are still looking for ways to trim their gas bill, especially on long road trips. AAA expects gas prices to stay around $3.33 going into Labor Day, close to last year’s average.

    Experts say identifying the cheapest gas stations and most fuel-efficient route — as well as keeping the windows closed while driving — can help improve mileage and save money.

    Drivers who haven’t picked out their refueling points in advance can “spend time driving extra to look for those gas stations,” wasting gas in the process, said Aixa Diaz, a spokesperson for AAA.

    Packing light can also help save on gas mileage, and bringing snacks and other necessities can limit the number of stops along the road, Diaz said.

    Have a cookout

    Rising grocery store prices are a major source of stress for Americans, especially as the cost of living increases.

    However, buying groceries is still cheaper than eating out. If you’re staying with family or renting a place for the weekend, consider a cookout instead of dining out, and try CNN’s tips for saving on food prices. Digital coupons, purchasing store brands and buying in bulk are just a few ways to cut costs at the grocery store.

    Stew Leonard Jr., president and CEO of Stew Leonard’s Grocery Stores, a chain of eight grocery stores in the Northeast, also recommends downloading your local grocer’s app to search for savings. Some apps allow customers to accrue points for rewards like free ice cream.

    Higher food prices have made grocery shopping more expensive, pushing many consumers to look for new savings. Credit: Cyndi Monaghan/Moment RF / Getty Images via CNN Newsource

    Research your beach

    Some popular beaches charge entrance and parking fees. Choosing a beach with free parking, no entrance fee, or both, might be a good option for budget-conscious sunbathing.

    Beaches in a few states, particularly in the Northeast, can also charge admission. If you plan on going multiple days to a beach that does, check if it offers week-long passes. Age is also a factor – some beaches give children or seniors discounts on admission prices, so those looking to qualify should bring their ID with them.

    For those planning to stay closer to home, find out if your city has free pools or if there are buses, shuttles or other transportation options to get to the beach. Carpooling is also a great way to split the cost of parking.

    Visit a free national park

    If the beach isn’t your thing, consider getting some fresh air in one of America’s 63 national parks.

    Check the National Park Service website to look for free parks in your area. Also, note that a government program allows any 4th graders in your family to access all national parks for free.

    Though they are operated by the government, not all national parks are free to visit, and costs vary between parks. The National Parks Service recommends looking into your park before your visit — checking for any entry fees, reservation times, and activities you might plan on doing.

    However, be warned – visitors have felt the pinch of staffing shortages at the parks in the wake of Trump administration’s layoffs at the National Park Service this year. Some visitors to national parks recently told CNN they noted a lack of educational programs offered, and had trouble picking up wilderness permits (a requirement some parks have for backpacking and overnight stays).

    [ad_2]

    CNN

    Source link

  • The Future of Obesity Drugs Just Got Way More Real

    The Future of Obesity Drugs Just Got Way More Real

    [ad_1]

    A wild idea recently circulated about the future of aviation: If passengers lose weight via obesity drugs, airlines could potentially cut down on fuel costs. In September, analysts at Jefferies Bank estimated that in the “slimmer society” obesity drugs will create, United Airlines could save up to $80 million in jet fuel annually.

    In the past year, as more Americans have learned about semaglutide, which is sold for diabetes under the brand name Ozempic and for obesity under the name Wegovy, hype has become completely divorced from reality. For all the grand predictions, just a fraction of Americans who qualify for obesity drugs are on them. With a list price of roughly $1,350 a month, Wegovy is far too expensive, under-covered by insurance, and in limited supply to be a routine part of health care.

    But that possibility is beginning to seem very real. The results of a highly anticipated study published on Saturday indicate that Wegovy can have profound effects on heart health, which potentially opens up the drug to even more patients. A few days earlier, the FDA approved Zepbound, an obesity drug that is a bit cheaper and appears more potent than Wegovy. If there was any doubt before, now it is undeniable: Obesity drugs “are here to stay,” Kyla Lara-Breitinger, a cardiologist at the Mayo Clinic, told me. “There’s only going to be more and more of them.” They are now poised to become deeply entrenched in American health care, perhaps eventually even joining the ranks of commonly used drugs such as statins and metformin.

    Considering that obesity is linked to all sorts of major heart ailments, it is no big surprise that a weekly shot for weight loss might have some cardiovascular benefits. But because this class of obesity drugs, known as GLP-1 agonists for the hunger hormone they target, is so new, doctors did not know that for sure. Starting in 2018, Novo Nordisk, the company that manufactures semaglutide, began to look for answers in a study of more than 17,600 people with obesity and cardiovascular disease. In this group, results of a trial named SELECT show that Wegovy reduced the risk of major cardiac events—stroke, heart attack, death—by 20 percent. Even compared with studies on common heart medications such as Praluent and Repatha, the Wegovy results are “impressive,” Eugene Yang, a cardiologist and professor of medicine at the University of Washington, told me.

    How exactly the drug prevents major cardiac events isn’t fully understood. Some of the effects can likely be chalked up to weight loss itself, which is associated with improvements in metrics that influence heart health, such as blood pressure, Yang said. But mechanisms independent of weight loss may also be at work. In the trial, lower rates of cardiovascular events began showing up before participants lost weight. One explanation is the drug’s impact on inflammation, which is associated with heart disease: C-reactive protein, a rough proxy for inflammation, dropped by nearly 40 percent in study participants.

    Regardless of how Wegovy works, Yang said, “it has the potential benefit of being very significant” as a new line of treatment for heart disease, the leading cause of death nationwide. Novo Nordisk has already applied for expanded FDA approval and anticipates receiving it within six months. Approval would also show that Wegovy has a medical benefit beyond weight loss, pressuring insurers to cover it. Right now, for instance, Medicare does not, in part because obesity has long been viewed as a cosmetic issue, not a medical one. Even with private coverage, the drug is still frequently out of reach. The SELECT trial makes it “unequivocally clear” that obesity is a health condition that can be treated with drugs, Ted Kyle, an obesity-policy expert, told me. Still, the study leaves room for pushback: The absolute risk reduction of cardiovascular events was 1.5 percent, which is, by some reckonings, quite small. A higher risk reduction would have “put more pressure” on insurers and manufacturers to make the drugs more affordable for Americans, Lara-Breitinger said.

    Still, the findings are robust enough that it seems likely that the heart benefits of obesity drugs will lead more Americans to take them—if not immediately, then eventually. The approval of a new drug could do the same. Tirzepatide, which Eli Lilly has sold as a diabetes drug under the name Mounjaro, will be marketed as Zepbound for obesity—and it is coming for Wegovy’s throne. In one study, people on tirzepatide lost an average of 18 percent of their body weight; for comparison, in another study patients on Wegovy lost an average of 15 percent. At a little over $1,000 a month, Zepbound is not cheap, but its list price is hundreds of dollars lower than that of Wegovy. (The manufacturers of both drugs have said that most insured patients pay far less than that.)

    Zepbound’s approval is just the beginning. Unlike semaglutide, which targets only one hormone, GLP-1, to exert its effects on appetite and fullness, tirzepatide targets two. Other drugs that target two or even three hormones are in the works, as are versions that come in a more appealing pill format rather than as an injection. Generic versions of these drugs, likely beginning with liraglutide, a predecessor to semaglutide sold as Saxenda, could become available soon, Yang said. This competition will help bring down costs, but it will go only so far. Drug pricing is “a little bit screwy,” Kyle said, complicated by the wide gap between the list price and the net price created by manufactures, insurers, and intermediaries between them.

    Each new competitor and new study is a step toward a future in which a substantial proportion of Americans with obesity are routinely prescribed these drugs. In a single week, obesity drugs leapt a new era—one in which they are about to become significantly more mainstream. No doubt that future is a bright one for millions of people who might benefit from treatment. Still, many questions about the drugs remain unanswered, such as their long-term safety and endless supply shortages.

    But the potential for obesity drugs to truly change America has never felt closer—with all of the dizzying questions this creates about what “a slimming society” might mean for exercise, the food industry, and apparently even airline jet fuel.

    [ad_2]

    Yasmin Tayag

    Source link